Oxurion NV (FRA:TG40)

Market Cap	248.34K -16.5%
Revenue (ttm)	555.00K +18,400.0%
Net Income	-3.73M
EPS	-0.13
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0002
Previous Close	0.0066
Day's Range	0.0002 - 0.0002
52-Week Range	0.0002 - 0.0312
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Oxurion NV

Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 26
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TG40

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error